Kenzolin Mechanism of Action

Pharmacology: Pharmacodynamics: Piperacillin is an antibiotic that has the ability to kill a wide variety of bacteria. It works by interfering with the formation of bacterial cell walls. It does this by preventing the bacteria from vital cross-links within their cell walls. These cross-links strengthen the cell walls and allow them to protect the bacteria from their environment. By interfering with the cross linking meshwork in the cell walls, piperacillin weakens them. The cell walls of bacteria are essential for their survival. They protect the bacteria from environment and keep unwanted substances from entering the cells. As piperacillin weakens the cell walls, it allows unwanted substances to enter the bacteria cells. This causes the cells to swell and eventually rupture, and kills the bacteria. Certain bacteria are resistant to penicillin-type antibiotics, because they have developed the ability to produce defensive chemicals. These chemicals are called beta-lactamases. They interfere with the structure of penicillin-type antibiotics and stop them from working. Tazobactam is a type of medicine known as beta-lactamase inhibitor. It is included in this medicine because it inhibits the action of the beta lactamases produced by certain bacteria. This prevents the bacteria from inactivating the piperacillin, and then leaves them susceptible to attack. Tazobactam therefore increases the range of bacteria that piperacillin can kill.
Pharmacokinetics: After the administration of single doses of piperacillin/tazobactam to subjects with renal impairment, the half life of piperacillin and tazobactam increases with decreasing creatinine clearance. At creatinine clearance below 20mL/min, the increase in half-life is twofold for piperacillin and fourfold for tazobactam compared to subjects with normal renal function. Piperacillin and tazobactam are widely distributed into tissues and body fluids including intestinal mucosa, gallbladder, lung, female reproductive tissues (uterus, ovary, and fallopian tube), interstitial fluid and bile.
Mean tissue concentrations are generally 50% to 100% of those in plasma. Distribution of piperacillin and tazobactam into cerebrospinal fluid is low in subjects with non-inflamed meninges, as with other penicillins. Piperacillin is metabolized to a minor microbiologically active desethyl metabolite. Tazobactam is metabolized to a single metabolite that lacks pharmacological and antibacterial activities. Both piperacillin and tazobactam are eliminated via the kidney by glomerular filtration and tubular secretion. Piperacillin is excreted rapidly as unchanged drug with 68% of the administered dose excreted in the urine. Tazobactam and its metabolite are eliminated primarily by renal excretion with 80% of the administered dose excreted as unchanged drug and the remainder as the single metabolite. Piperacillin, tazobactam and desethyl piperacillin are also secreted into the bile.